Micrograph showing prostatic acinar adenocarcinoma - the most common form of...
Micrograph showing prostatic acinar adenocarcinoma - the most common form of prostate cancer.
Source: Wikipedia

Using AI to detect and grade prostate cancer

Researchers at Karolinska Institutet have developed a method based on artificial intelligence for histopathological diagnosis and grading of prostate cancer. The AI-system has the potential to solve one of the bottlenecks in today’s prostate cancer histopathology by providing more accurate diagnosis and better treatment decisions.

The study shows that the AI-system is as good at identifying and grading prostate cancer as world-leading uro-pathologists. “Our results show that it is possible to train an AI-system to detect and grade prostate cancer on the same level as leading experts,” says Martin Eklund, associate professor at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet who led the study. “This has the potential to significantly reduce the workload of uro-pathologists and allow them to focus on the most difficult cases.”

A problem in today’s prostate pathology is that there is a certain degree of subjectivity in the assessments of the biopsies. Different pathologists can reach different conclusions even though they are studying the same samples. This leads to a clinical problem where the doctors must pick treatment based on ambiguous information. In this context, the researchers see significant potential to use the AI-technology to increase the reproducibility of the pathological assessments.

To train and test the AI system, the researchers digitized more than 8,000 biopsies taken from some 1,200 Swedish men in the ages of 50–69 to high-resolution images using digital pathology scanners. About 6,600 of the samples were used to train the AI system to spot the difference between biopsies with or without cancer. The remaining samples, and additional sets of samples collected from other labs, were used to test the AI system. Its results were also compared against the assessments of 23 world-leading uro-pathologists. The study was conducted in collaboration with researchers at Tampere University in Finland.

Near-perfect detection

The findings showed that the AI-system was almost near-perfect in determining whether a sample contained cancer or not, as well as in estimating the length of the cancer tumor in the biopsy. When it comes to determining the severity of the prostate cancer, the so-called Gleason score, the AI system was on par with the international experts. “When it comes to grading the severity of the prostate cancer, the AI is in the same range as international experts, which is very impressive, and when it comes to diagnostics, to determine whether or not it is cancer, the AI is simply outstanding,” says Lars Egevad, professor in pathology at Karolinska Institutet and co-author of the study.

The initial findings are promising but more validation is needed before the AI system may be rolled out broadly in clinical practice, according to the researchers. That is why a multicenter study spanning nine European countries is currently underway with completion slated by the end of 2020. That study, which is financed by EIT Health, aims to train the AI-system to recognize cancer in biopsies taken from different laboratories, with different types of digital scanners and with very rare growth patterns. In addition, a randomized study starting in 2020 will examine how the AI-model may be implemented in Sweden’s health care system. “AI-based evaluation of prostate cancer biopsies could revolutionize future health care,” says Henrik Grönberg, professor in cancer epidemiology at Karolinska Institutet and head of the Prostate Cancer Center at S:t Göran Hospital in Stockholm. “It has the potential to improve the diagnostic quality, and thereby secure a more equitable care at a lower cost.”

“The idea is not that AI should replace the human involvement, but rather act as a safety net to ensure that pathologists don’t miss some cancers, and assist in standardization of grading,” says Martin Eklund. “It could also serve as an alternative in parts of the world where there is a complete lack of pathological expertise today.”

Subscribe to our newsletter

Related articles

AI taps human wisdom for better cancer diagnosis

AI taps human wisdom for better cancer diagnosis

A new system combining artificial intelligence with human knowledge promises faster and more accurate cancer diagnosis.

Using AI to predict risk of thyroid cancer on ultrasound

Using AI to predict risk of thyroid cancer on ultrasound

Researchers from Thomas Jefferson University use machine learning on ultrasound images of thyroid nodules to predict risk of malignancy.

Towards an AI diagnosis like the doctor's

Towards an AI diagnosis like the doctor's

Researchers show how they can make an AI show how it's working, as well as let it diagnose more like a doctor, thus making AI-systems more relevant to clinical practice.

Huge potential of human - AI collaboration

Huge potential of human - AI collaboration

AI is increasingly being used in medicine to support human expertise. A study has now illustrated the enormous potential of human/computer collaboration.

Lung cancer: AI could predict risk of recurrence

Lung cancer: AI could predict risk of recurrence

Computer scientists working with pathologists have trained an AI tool to determine which patients with lung cancer have a higher risk of their disease coming back after treatment.

Deep learning accurately stains digital biopsy slides

Deep learning accurately stains digital biopsy slides

Pathologists who examined the computationally stained images could not tell them apart from traditionally stained slides.

AI model accurately classifies colorectal polyps

AI model accurately classifies colorectal polyps

An AI model for automated classification of colorectal polyps could benefit cancer screening programs by improving efficiency, reproducibility, and accuracy.

Hybrid microscope could bring digital biopsy to the clinic

Hybrid microscope could bring digital biopsy to the clinic

By adding infrared capability to the ubiquitous, standard optical microscope, researchers hope to bring cancer diagnosis into the digital era.

AI tracks down acute myeloid leukemia

AI tracks down acute myeloid leukemia

Artificial intelligence can detect one of the most common forms of blood cancer—acute myeloid leukemia (AML)—with high reliability.

Popular articles